Systemic and portal hemodynamic effects of anandamide

Nelson Garcia, Z. Járai, Faridoddin Mirshahi, George Kunos, Arun J. Sanyal

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The endogenous cannabinoid anandamide causes hypotension and mesenteric arteriolar dilation. A detailed analysis of its effects on systemic and portal venous hemodynamics had not yet been performed. We assessed the effects of anandamide (0.4-10 mg/kg) on systemic and portal hemodynamics with and without prior treatment with various antagonists. The specific antagonists used included SR-141716A, Nω-nitro-L-arginine methyl ester, indomethacin, and nordihydroguaiaretic acid. Anandamide produced a dose-dependent decrease in mean arterial pressure due to a drop in systemic vascular resistance (SVR) that was accompanied by a compensatory rise in cardiac output. Anandamide also elicited an increase in both portal venous flow and pressure, along with a decline in mesenteric vascular resistance (MVR). Pretreatment with 3 mg/kg SR-141716A, a CB1 antagonist, prevented the decline of SVR and MVR from the lower dose of anandamide. Antagonism of nitric oxide synthetase, cyclooxygenase, or 5-lipoxygenase did not prevent the systemic nor the portal hemodynamic effects of anandamide. Furthermore, the use of R-methanandamide, a stable analog of anandamide, produced similar hemodynamic effects on the mesenteric vasculature, thereby implying that the effects of anandamide are not related to its breakdown products. Anandamide produced profound, dose-dependent alterations in both the systemic and portal circulations that could be at least partially blocked by pretreatment with SR-141716A.

Original languageEnglish
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume280
Issue number1 43-1
Publication statusPublished - Jan 2001

Fingerprint

rimonabant
Hemodynamics
Vascular Resistance
Masoprocol
anandamide
Portal Pressure
Arachidonate 5-Lipoxygenase
Cannabinoids
Prostaglandin-Endoperoxide Synthases
Nitric Oxide Synthase
Indomethacin
Cardiac Output
Hypotension
Dilatation
Arterial Pressure

Keywords

  • Blood pressure
  • Cannabinoids
  • Cirrhosis
  • Portal hypertension
  • Portal vein flow
  • Portal vein pressure
  • Splanchnic blood flow
  • SR-141716A

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology
  • Physiology (medical)

Cite this

Systemic and portal hemodynamic effects of anandamide. / Garcia, Nelson; Járai, Z.; Mirshahi, Faridoddin; Kunos, George; Sanyal, Arun J.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 280, No. 1 43-1, 01.2001.

Research output: Contribution to journalArticle

Garcia, Nelson ; Járai, Z. ; Mirshahi, Faridoddin ; Kunos, George ; Sanyal, Arun J. / Systemic and portal hemodynamic effects of anandamide. In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 2001 ; Vol. 280, No. 1 43-1.
@article{2ad6c73a589948f3a0f998e91a0d88eb,
title = "Systemic and portal hemodynamic effects of anandamide",
abstract = "The endogenous cannabinoid anandamide causes hypotension and mesenteric arteriolar dilation. A detailed analysis of its effects on systemic and portal venous hemodynamics had not yet been performed. We assessed the effects of anandamide (0.4-10 mg/kg) on systemic and portal hemodynamics with and without prior treatment with various antagonists. The specific antagonists used included SR-141716A, Nω-nitro-L-arginine methyl ester, indomethacin, and nordihydroguaiaretic acid. Anandamide produced a dose-dependent decrease in mean arterial pressure due to a drop in systemic vascular resistance (SVR) that was accompanied by a compensatory rise in cardiac output. Anandamide also elicited an increase in both portal venous flow and pressure, along with a decline in mesenteric vascular resistance (MVR). Pretreatment with 3 mg/kg SR-141716A, a CB1 antagonist, prevented the decline of SVR and MVR from the lower dose of anandamide. Antagonism of nitric oxide synthetase, cyclooxygenase, or 5-lipoxygenase did not prevent the systemic nor the portal hemodynamic effects of anandamide. Furthermore, the use of R-methanandamide, a stable analog of anandamide, produced similar hemodynamic effects on the mesenteric vasculature, thereby implying that the effects of anandamide are not related to its breakdown products. Anandamide produced profound, dose-dependent alterations in both the systemic and portal circulations that could be at least partially blocked by pretreatment with SR-141716A.",
keywords = "Blood pressure, Cannabinoids, Cirrhosis, Portal hypertension, Portal vein flow, Portal vein pressure, Splanchnic blood flow, SR-141716A",
author = "Nelson Garcia and Z. J{\'a}rai and Faridoddin Mirshahi and George Kunos and Sanyal, {Arun J.}",
year = "2001",
month = "1",
language = "English",
volume = "280",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "1 43-1",

}

TY - JOUR

T1 - Systemic and portal hemodynamic effects of anandamide

AU - Garcia, Nelson

AU - Járai, Z.

AU - Mirshahi, Faridoddin

AU - Kunos, George

AU - Sanyal, Arun J.

PY - 2001/1

Y1 - 2001/1

N2 - The endogenous cannabinoid anandamide causes hypotension and mesenteric arteriolar dilation. A detailed analysis of its effects on systemic and portal venous hemodynamics had not yet been performed. We assessed the effects of anandamide (0.4-10 mg/kg) on systemic and portal hemodynamics with and without prior treatment with various antagonists. The specific antagonists used included SR-141716A, Nω-nitro-L-arginine methyl ester, indomethacin, and nordihydroguaiaretic acid. Anandamide produced a dose-dependent decrease in mean arterial pressure due to a drop in systemic vascular resistance (SVR) that was accompanied by a compensatory rise in cardiac output. Anandamide also elicited an increase in both portal venous flow and pressure, along with a decline in mesenteric vascular resistance (MVR). Pretreatment with 3 mg/kg SR-141716A, a CB1 antagonist, prevented the decline of SVR and MVR from the lower dose of anandamide. Antagonism of nitric oxide synthetase, cyclooxygenase, or 5-lipoxygenase did not prevent the systemic nor the portal hemodynamic effects of anandamide. Furthermore, the use of R-methanandamide, a stable analog of anandamide, produced similar hemodynamic effects on the mesenteric vasculature, thereby implying that the effects of anandamide are not related to its breakdown products. Anandamide produced profound, dose-dependent alterations in both the systemic and portal circulations that could be at least partially blocked by pretreatment with SR-141716A.

AB - The endogenous cannabinoid anandamide causes hypotension and mesenteric arteriolar dilation. A detailed analysis of its effects on systemic and portal venous hemodynamics had not yet been performed. We assessed the effects of anandamide (0.4-10 mg/kg) on systemic and portal hemodynamics with and without prior treatment with various antagonists. The specific antagonists used included SR-141716A, Nω-nitro-L-arginine methyl ester, indomethacin, and nordihydroguaiaretic acid. Anandamide produced a dose-dependent decrease in mean arterial pressure due to a drop in systemic vascular resistance (SVR) that was accompanied by a compensatory rise in cardiac output. Anandamide also elicited an increase in both portal venous flow and pressure, along with a decline in mesenteric vascular resistance (MVR). Pretreatment with 3 mg/kg SR-141716A, a CB1 antagonist, prevented the decline of SVR and MVR from the lower dose of anandamide. Antagonism of nitric oxide synthetase, cyclooxygenase, or 5-lipoxygenase did not prevent the systemic nor the portal hemodynamic effects of anandamide. Furthermore, the use of R-methanandamide, a stable analog of anandamide, produced similar hemodynamic effects on the mesenteric vasculature, thereby implying that the effects of anandamide are not related to its breakdown products. Anandamide produced profound, dose-dependent alterations in both the systemic and portal circulations that could be at least partially blocked by pretreatment with SR-141716A.

KW - Blood pressure

KW - Cannabinoids

KW - Cirrhosis

KW - Portal hypertension

KW - Portal vein flow

KW - Portal vein pressure

KW - Splanchnic blood flow

KW - SR-141716A

UR - http://www.scopus.com/inward/record.url?scp=0343831464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343831464&partnerID=8YFLogxK

M3 - Article

C2 - 11123193

AN - SCOPUS:0343831464

VL - 280

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 1 43-1

ER -